Ballard Spahr Represents OMERS Life Sciences in Royalty Transaction

Ballard Spahr represented OMERS Life Sciences with respect to patent matters in its $200 million purchase of 54.5 percent of future royalty payments to Enanta Pharmaceuticals (NASDAQ: ENTA) from AbbVie Inc. on global sales of MAVYRET/MAVIRET chronic hepatitis C treatment.

OMERS Life Sciences provides royalty financings and other non-dilutive solutions to biopharma companies and academic institutions, supporting their efforts to address unmet medical needs and improve the quality of life of patients around the world. OMERS Life Sciences invests on behalf of OMERS, one of Canada’s largest defined benefit pension plans.

Intellectual Property Partners Kenneth H. Sonnenfeld, Ph.D. and Margaret “Peg” Bolce Brivanlou, Ph.D. led the Ballard Spahr team that represented OMERS on patent matters. It included Intellectual Property Attorney Kristine Waddell and patent agents Alexander M. Porte, Ph.D. and Kaori Watanabe, Ph.D.

For further information, please see Enanta’s press release.

For media inquiries, please contact Will Ashenmacher at 612.371.5792.